睿昂基因：预计2025年全年净亏损3990.69万元—5986.03万元

Core Viewpoint - Ruiang Gene has announced an annual performance forecast indicating a significant decline in net profit for 2025, with expected losses ranging from 39.91 million to 59.86 million yuan, primarily due to intensified competition in the in vitro diagnostics industry and other adverse factors [1] Group 1: Financial Performance - The company anticipates a decrease in operating revenue for 2025, projected to fall between 66.31 million and 72.31 million yuan, representing a year-on-year decline of approximately 27.36% to 29.84% [1] - The net profit attributable to the parent company and the net profit after deducting non-recurring gains and losses are both expected to show a substantial decline compared to the previous year [1] Group 2: Contributing Factors - The decline in revenue is attributed to intensified competition in the in vitro diagnostics sector and specific adverse events affecting the company [1] - The company has increased provisions for credit impairment losses on accounts receivable due to slower payment from downstream customers influenced by the medical industry environment [1] - The company has recognized impairment losses on its molecular diagnostic reagent R&D center and industrialization project, which has been suspended with no plans for resumption [1] - Impairment losses have also been recognized for subsidiaries Shanghai Yuanqi Bio and Wuhan Baitai due to further declines in their performance and indications of asset impairment [1] - The overall performance decline of both the parent and subsidiary companies has led to a reassessment of future taxable income, resulting in the write-off of previously recognized deferred tax assets [1]